Literature DB >> 15610669

Recent Developments in Leishmaniasis: Epidemiology, Diagnosis, and Treatment.

Jonathan Berman1.   

Abstract

The outbreaks of cutaneous disease caused by Leishmania tropica in Afghan refugees, visceral disease in Sudanese refugees, and cutaneous disease caused by Leishmania major in American forces in Iraq are examples of the large number of cases of leishmaniasis that can result when naive human populations intrude into regions where transmission is endemic. Injections of pentavalent antimony for 20 to 30 days have been the standard treatment for all forms of leishmaniasis, but resistance is growing and antimonials have moderate toxicity. Two major advances in the treatment of visceral leishmaniasis have been made in the past few years. Liposomal amphotericin B cures virtually all patients, with little side effects. Miltefosine is the first oral agent that is effective. For cutaneous disease, alternatives to antimony have been effective in certain regions but have not yet been generally evaluated.

Entities:  

Year:  2005        PMID: 15610669     DOI: 10.1007/s11908-005-0021-1

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  30 in total

1.  Worldwide increasing risk factors for leishmaniasis.

Authors:  P Desjeux
Journal:  Med Microbiol Immunol       Date:  2001-11       Impact factor: 3.402

2.  Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer.

Authors:  Paulo Machado; Cibele Araújo; Andréa T Da Silva; Roque P Almeida; Argemiro D'Oliveira Jr; Achiléa Bittencourt; Edgar M Carvalho
Journal:  Clin Infect Dis       Date:  2002-05-17       Impact factor: 9.079

3.  Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species.

Authors:  R Palacios; L E Osorio; L F Grajalew; M T Ochoa
Journal:  Am J Trop Med Hyg       Date:  2001 Mar-Apr       Impact factor: 2.345

4.  Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.

Authors:  K Ritmeijer; H Veeken; Y Melaku; G Leal; R Amsalu; J Seaman; R N Davidson
Journal:  Trans R Soc Trop Med Hyg       Date:  2001 Nov-Dec       Impact factor: 2.184

5.  A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan.

Authors:  H Veeken; K Ritmeijer; J Seaman; R Davidson
Journal:  Trop Med Int Health       Date:  2000-05       Impact factor: 2.622

6.  Diagnosis of cutaneous leishmaniasis in Colombia: the sampling site within lesions influences the sensitivity of parasitologic diagnosis.

Authors:  J R Ramírez; S Agudelo; C Muskus; J F Alzate; C Berberich; D Barker; I D Velez
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

Review 7.  The epidemiology and control of leishmaniasis in Andean countries.

Authors:  C R Davies; R Reithinger; D Campbell-Lendrum; D Feliciangeli; R Borges; N Rodriguez
Journal:  Cad Saude Publica       Date:  2000 Oct-Dec       Impact factor: 1.632

8.  Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study.

Authors:  Jaime M Soto; Julia T Toledo; Patricia Gutierrez; Margarita Arboleda; Ruben S Nicholls; Julio R Padilla; Jonathan D Berman; Charles K English; Max Grogl
Journal:  Am J Trop Med Hyg       Date:  2002-02       Impact factor: 2.345

9.  Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.

Authors:  S Sundar; T K Jha; C P Thakur; M Mishra; V R Singh; R Buffels
Journal:  Am J Trop Med Hyg       Date:  2002-02       Impact factor: 2.345

10.  Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala.

Authors:  T R Navin; B A Arana; F E Arana; J D Berman; J F Chajón
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

View more
  9 in total

1.  Quantitative nucleic acid sequence-based assay as a new molecular tool for detection and quantification of Leishmania parasites in skin biopsy samples.

Authors:  Wendy F van der Meide; Gerard J Schoone; William R Faber; Jim E Zeegelaar; Henry J C de Vries; Yusuf Ozbel; Rudy F M Lai A Fat; Leíla I A R C Coelho; Masoom Kassi; Henk D F H Schallig
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

2.  Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis.

Authors:  Samuel Vidal Mussi; Ana Paula Fernandes; Lucas Antonio Miranda Ferreira
Journal:  Parasitol Res       Date:  2007-01-06       Impact factor: 2.289

3.  Novel noninvasive method for diagnosis of visceral leishmaniasis by rK39 testing of sputum samples.

Authors:  D Singh; K Pandey; V N R Das; S Das; S Kumar; R K Topno; P Das
Journal:  J Clin Microbiol       Date:  2009-06-10       Impact factor: 5.948

Review 4.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

5.  New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.

Authors:  Kathryn M Dupnik; Eliana L Nascimento; Joao F Rodrigues-Neto; Tatjana Keesen; Maria Zélia Fernandes; Iraci Duarte; Selma M B Jeronimo
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

6.  Why strategies to control Leishmania spp. multiplication based on the use of proteinase inhibitors should consider multiple targets and not only a single enzyme.

Authors:  Carlos Roberto Alves; Bernardo Acácio Santini Pereira; Mariana Silva-Almeida; Franklin Souza da Silva
Journal:  J Mol Model       Date:  2014-10-09       Impact factor: 1.810

7.  In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: antiproliferative, biochemical, and ultrastructural effects.

Authors:  Juliany Cola Fernandes Rodrigues; Juan Luis Concepcion; Carlos Rodrigues; Aura Caldera; Julio A Urbina; Wanderley de Souza
Journal:  Antimicrob Agents Chemother       Date:  2008-09-02       Impact factor: 5.191

8.  Inhibition of growth of Leishmania donovani promastigotes by newly synthesized 1,3,4-thiadiazole analogs.

Authors:  Ahmed Al-Qahtani; Yunus M Siddiqui; Adnan A Bekhit; Ola A El-Sayed; Hassan Y Aboul-Enein; Mohammed N Al-Ahdal
Journal:  Saudi Pharm J       Date:  2009-08-07       Impact factor: 4.330

9.  Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.

Authors:  Dae Hyun Kim; Hye Jin Chung; Joachim Bleys; Reza F Ghohestani
Journal:  PLoS Negl Trop Dis       Date:  2009-02-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.